Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic. TARGET is a molecular profiling program with the primary aim to match patients with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of both somatic mutations and copy number alterations (CNA) across a 641 cancer-associated-gene panel in a single ctDNA assay. For the first 100 TARGET patients, ctDNA data showed good concordance with matched tumor and results were turned round within a clinically acceptable timeframe for Molecular Tumor Board (MTB) review. When a 2.5% variant allele frequency (VAF) threshold was applied, actionable mutations were identified in 41 of 100 patients, and 11 of these patients received a matched therapy. These data support the application of ctDNA in this early phase trial setting where broad genomic profiling of contemporaneous tumor material enhances patient stratification to novel therapies and provides a practical template for bringing routinely applied blood-based analyses to the clinic.
. However, genomic profiling of archival specimens can be limited by sample age, quality, low tumor content and tumor heterogeneity. Also, archival samples by their very nature, do not take into account ongoing tumor evolution, particularly if patients have received therapies which may confer acquired resistance. Acquisition of fresh tissue is often challenging and not without patient risk, yet there is increasing demand for tumor material in the context of clinical trials and molecular profiling. ctDNA is extractable from a peripheral blood sample and provides a contemporaneous profile of the tumor genomic landscape.
NGS technology has evolved for reliable sequencing of ctDNA 10, 11 , but clinical validation is needed to drive forward routine use of ctDNA in the clinic 12 . The TARGET (Tumour chARacterisation to Guide Experimental Targeted therapy) study was designed to determine the feasibility of using ctDNA, relative to tissue-based testing, to identify clinically actionable mutations in early phase clinical trial patients with a range of advanced-stage cancers (Fig. 1a) . Our study was divided into Part A (100 patients) to establish an analytical workflow and assess feasibility of data turnaround in a timeframe of 2-4 weeks to support clinical decision-making, and Part B (450 patients) to test clinical utility following selection of patients in real time to molecularly matched trials on the basis of their ctDNA and/or tumor genomic profile. Here we present data from Part A of the TARGET trial, demonstrating the 'real world' feasibility for routine implementation of ctDNA profiling to increase the chance of matching patients with advanced cancers to a phase I trial of an appropriate targeted therapy.
Blood samples from the first 20 patients were used to optimize the ctDNA workflow, with automated ctDNA purification demonstrating comparable yields to manual isolations (Extended Data Fig.  1a ). Hybridization and enrichment of a 2.1-megabase (Mb) Agilent SureSelect panel targeting 641 genes recurrently mutated in cancers (Supplementary Table 1 ) to the ctDNA library and germline control for each patient, resulted in an average 1,322-fold enrichment (range 359-5,804) of targeted genes (Extended Data Fig. 1b ). Sensitivity and reproducibility of the NGS assay were tested on a reference panel of five samples with highly characterized genotypes from the European Molecular Genetics Quality Network. All 14 reference mutations in the five samples were detected with 100% specificity and sensitivity and >90% correlation of expected allele frequency across all mutations detected (Extended Data Fig. 1c) .
Having demonstrated the reliability of the ctDNA workflow, we expanded the cohort to 100 patients referred to the Experimental Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study Dominic TAR081   TAR082   TAR083   TAR084   TAR085   TAR086   TAR087   TAR088   TAR089   TAR090   TAR091   TAR092   TAR093   TAR094   TAR095   TAR096   TAR097   TAR098   TAR099 TAR001  TAR002  TAR003  TAR004  TAR005  TAR006  TAR007  TAR008  TAR009  TAR010  TAR011  TAR012  TAR013  TAR014  TAR015  TAR016  TAR017  TAR018  TAR019  TAR020  TAR021  TAR022  TAR023  TAR024  TAR025  TAR026  TAR027  TAR028  TAR029  TAR030  TAR031  TAR032  TAR033  TAR034  TAR035  TAR036  TAR037  TAR038  TAR039  TAR040  TAR041  TAR042  TAR043  TAR044  TAR045  TAR046  TAR047  TAR048  TAR049  TAR050  TAR051  TAR052  TAR053  TAR054  TAR055  TAR056  TAR057  TAR058  TAR059  TAR060  TAR061  TAR062  TAR063  TAR064  TAR065  TAR066  TAR067  TAR068  TAR069  TAR070  TAR071  TAR072  TAR073  TAR074  TAR075  TAR076  TAR077  TAR078  TAR079  TAR080  TAR081  TAR082  TAR083  TAR084  TAR085  TAR086  TAR087  TAR088  TAR089  TAR090  TAR091  TAR092  TAR093  TAR094  TAR095  TAR096  TAR097  TAR098  TAR099  TAR100 Fig. 1 | Overview of analysis of the first 100 patients recruited to the TARGET study. a, Outline of the approaches used for ctDNA and tumor analysis in the TARGET study. b, Average de-duplicated read depth for first 100 TARGET patients. A threshold of ≥100 average de-duplicated reads was set as a quality control for reporting data to the MTB (blue line). Reporting rate for tumor is indicated below the graph, with failed samples indicated in red boxes, successful samples in green boxes. The age of tumor biopsies at the time of analysis is indicated below the graph with biopsies <1 year old, 1-3 years and >3 years old indicated. c, Reporting times from the time of blood collection to generation of variant report for submission to the MTB in calendar days is shown for patients TAR-081 to TAR-100. The average time taken for patients 21-100 for ctDNA (mean = 33 days, s.d. = ±9 days, n = 80) and tumor (mean = 30 days, s.d. = ±15 days, n = 75) is indicated at the bottom of the graph. Calendar days taken to complete ctDNA isolation (red box), NGS generation (gray box) and bioinformatic analysis (blue box) are indicated. d, Bar graph showing concordance of mutations detected across 19-and 24-gene clinical panels in tumor and ctDNA for first 100 TARGET patients. Graph shows number of high confidence concordant mutations (dark green), mutations found below the 2.5% VAF level of detection (light green) and discordant mutations (red). e, Bar graph showing concordance of 94 TARGET patients for whom combined tumor and ctDNA data were available. Concordant patients are indicated in blue (dark blue, no mutations detected; light blue concordant mutations detected) and discordant patients in gray (light gray, mutation present only in tumor; dark gray, mutation present only in ctDNA). f, Table 3 ). In this cohort of patients, 67% of tumor biopsies were >1 year old and 36% were >3 years old (range 0-5,635 days pre-blood collection) (Fig. 1b) , highlighting the benefit of ctDNA sampling. Critical to any molecular profiling program is turnaround of results within a meaningful timeframe to facilitate clinical decisionmaking for an individual patient, and to minimize the risk of dropout from clinical trial participation due to declining health. Our data show comparable report times for formalin-fixed paraffinembedded (FFPE) tumor tissue analysis and ctDNA; with a mean report time from blood draw of 33 calendar days (range 20-80) for patients 21-100, comparable with a mean tumor DNA report time of 30 calendar days (range 17-140) from date of consent to receipt of result (Fig. 1c) .
All tumor samples were analyzed in a National Health Service (NHS), ISO15189-accredited clinical laboratory, initially using a 19-gene MassArray assay (Sequenom OncoCarta v1.0; 57% patients) and more recently a 24-gene GeneRead PCR amplicon assay (Qiagen Clinically Relevant Tumor Targeted Panel V2; 43% patients), which represent cancer panel assays clinically accredited in the UK NHS at the time of the study. A total of 69 non-synonymous mutations were identified in tumors across 54 patients, with no mutations reported for the remainder. Analysis of the corresponding mutations in the ctDNA NGS data revealed good concordance, with 54/69 mutations (78.3%) also detected ( Fig. 1d and Extended Data Fig. 3 ). This level of concordance, even accounting for differences between gene panels and levels of sensitivity between the tumor and ctDNA assays, compares favorably with other recently described studies 10, 13, 14 . The ctDNA assay was also compared with the FoundationOne panel in a subset of 39 patients where the matched tumor also underwent Foundation Medicine testing (Supplementary Table 4 ). This enabled analysis across a broader panel of 230 genes present in both the 641-gene and FoundationOne panels. In this patient subset, 74 mutations were reported in the ctDNA, of which 52 were also reported in the tumor (70% concordance). A larger number of mutations were reported in the FoundationOne tumor analysis for these patients, which probably reflects a combination of a high tumor fraction in the input DNA and the ability to identify mutations belonging to minor tumor subclones that could not be picked up in ctDNA (Extended Data Fig. 4) .
For reporting mutations to the MTB, we applied a 2.5% VAF threshold to ensure reliability and robustness. Although more sensitive approaches are available 13 , our rationale for TARGET was to evaluate whether a 2.5% VAF cut-off was suitable for clinical application and treatment decision-making for phase I patients with advanced disease often having exhausted other treatment options. It has been shown that ctDNA yield is linked to tumor cell proliferation and death rates 15, 16 and therefore all ctDNA-based assays may have some bias toward higher tumor burden that should be taken into consideration when interpreting associated results. With this in mind, we asked whether the higher VAF threshold used here would result in bias toward patients with higher ctDNA yield or higher tumor burden. We did not find a significant correlation between VAF and ctDNA yield (Extended Data Fig. 5a ,b), which may be due to our cohort being phase I clinical trial patients, who will tend to have a large tumor burden and ctDNA yield. However, a significant correlation was observed between average VAF and number of metastatic sites (P = 0.0118), which was used here as a surrogate of tumor burden (Extended Data Fig. 5c,d ). While our 2.5% VAF threshold might result in 'false negatives' and inherently bias toward patients with higher disease burden, it will reduce 'false positives' and the assay facilitates broad panel testing for a diverse range of alterations required in the phase I trial setting, compared with smaller panel or single-gene assays where the sensitivity may be higher.
Using the 2.5% VAF threshold, 70/94 patients with both tumor and ctDNA analyzed showed concordance of reported mutations (74.5%) (Fig. 1e ). Discordance occurred in 24 patient samples: 20/24 had tumor mutations undetected in ctDNA (9 of these mutations were detectable in ctDNA, but below the 2.5% VAF threshold) and 4/24 had mutations in ctDNA, but not corresponding tumor. No correlation between tumor biopsy age and mutation discordance with ctDNA was evident (Extended Data Fig. 6 ). Where discordance was seen, this could often be ascribed to either a biological or clinical consequence: for example, TAR-039, a patient with colorectal cancer exhibited a KRAS c.34G>T (p.Gly12Cys) mutation in their ctDNA (VAF 3.4%), which was not detected in the archival tumor specimen collected 26 months previously. This is probably linked to the administration of anti-EGFR therapy (panitumumab) in the intervening period, to which KRAS mutation is a well-described mechanism of resistance 17 . A 641-gene panel was designed for application in the early phase 'all cancer types' trial setting because of its potential to provide a broader coverage of alterations/co-mutations, mechanisms of resistance and to facilitate the selection of novel targeted agents. The ctDNA assay provided a broad view of the mutational landscape across the various cancer types, with ≥1 mutation detected in 70% of patients (Extended Data Fig. 7 and Supplementary Table 5 ). Clear differences were seen in the number and allele frequencies of mutations across tumor types (Fig. 1f) , although patient numbers were too small to assign significance. We propose that this ctDNA assay will be most useful for certain patient populations/histological subtypes, since in our study no mutations were detected in 
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NATuRE MEDICINE certain tumor types (for example, adrenal cancer), whereas in others (for example, breast cancer, small-cell lung cancer and cancer of unknown primary) >80% patients had detectable ctDNA mutations. These data are based on limited patient numbers and could be confounded by differences in tumor volume and, as such, require validation in larger patient cohorts.
Another advantage of the broad panel targeted enrichment approach is that it enables evaluation of CNA, as well as mutation profiling within the same assay. The , and in 23 patients where the matched tumor had CNA reported following FoundationOne analysis ( Fig. 2a and Supplementary Table 4) . High concordance was seen between genome-wide CNA analysis of the 641-gene pulldown ctDNA and low-pass WGS profiles (Extended Data Fig. 8) . Concordant gene-level alterations were detected in 11/23 (48%) patients with both tumor FoundationOne and ctDNA analysis available (Extended Data Fig. 9 and Supplementary Table 6 ). As previously reported 21, 22 , accurate CNA calling from ctDNA requires a higher fraction of ctDNA in the sample, and when we applied an average VAF ≥ 5% threshold (15/23 patients) for CNA analysis, concordance with tumor increased to 11/15 (73%, Extended Data Fig. 9 ).
An important aim for Part A of TARGET was to establish a routine MTB for formal reporting and discussion of tumor and ctDNA mutational profiles of the 100 Part A patients. A challenge identified at the MTB was efficient and effective integration of clinical and genomic data. This prompted the development of eTARGET, an in-house digital solution integrating a single overview of patients' clinical and genomic characteristics. eTARGET includes a storage account for data upload, a database for storing and integrating data and a web application for data visualization (Extended Data Fig. 10 ). eTARGET enables the MTB to review summary patient data via a single portal (and remotely if required), capture meeting outcomes in real time and upload information to electronic patient records.
A potential reason why large molecular screening programs have traditionally allocated only 10-15% of patients to studies may be in the interpretation of variants of unknown significance [7] [8] [9] . It is challenging for any MTB to have knowledge of all possible variants, and databases are in development for pooling relevance of variants of unknown significance 23, 24 . We addressed this issue by accessing software packages to aid interpretation of the relevance of specific variants and to identify appropriate trials in different regions of the United Kingdom or Europe. The Qiagen Clinical Interface software package was considered valuable in differentiating actionable mutations (and recommended matched therapies) from those of unlikely clinical relevance, and provided tiering following ACMG/AMP/ CAP guidelines.
Following MTB review, 41 of the first 100 TARGET patients had an alteration considered to be actionable, of whom 11 received a matched therapy, 17 received a non-matched therapy (largely due to trial availability at site) and 13 either had no trial available, did not meet study specific eligibility, deteriorated clinically or went on to a chemotherapy option (Fig. 2b,c) . For the 11 patients that received a matched therapy, partial response was achieved in 4/11 and stable disease (minimum of 3 months) was observed in 7/11 patients. Median duration on therapy was 6 months (range 1.5-20 months) (Fig. 2d) . Of the 17 patients that received non-matched therapy 0/17 showed response to therapy and 4/17 achieved stable disease (Fig.  2c ). An example of a patient matched to a clinical trial, on the basis of ctDNA analysis following discussion at the MTB, is patient TAR-012; a 57-year-old female with lung adenocarcinoma who progressed through first-line cisplatin-pemetrexed chemotherapy. ctDNA profiling revealed an NRAS c.181C>A (p.Gln61Lys) mutation, also confirmed in her archival tumor. The patient was matched to a phase I trial of a first-in-human MEK inhibitor and demonstrated partial response with 60% reduction in marker lesions (RECIST 1.1) and symptomatic benefit (Fig. 2e) . Her disease remained controlled for 12 months. The clinical and radiological response demonstrated in this patient with NRAS-positive non-small-cell lung carcinoma to single-agent MEK inhibition is in keeping with preclinical data that strongly support this therapeutic approach 25 . The overall intent of TARGET was to develop a robust workflow supporting clinical decision-making that can be delivered on a routine basis, with a data turnaround time compatible with clinical practice and at an affordable cost (approximately £1,600 per patient) that leads to benefit in a proportion of phase I trial patients. With the feasibility of the workflow demonstrated in Part A, Part B of TARGET was initiated in February 2017 with the intention to recruit a further 450 patients over 3 years. In Part B, our primary aim is to improve matching of patients to clinical trials according to the molecular profile of their cancer and data will be prospectively collected for overall response rates and clinical outcomes for all patients to compare between matched and non-matched therapies. The turnaround time of results will also be shortened to 15-20 calendar days.
Our experience on the TARGET study encourages routine implementation of ctDNA testing as an adjunct to tumor testing. We suggest that with increased experience and ongoing development of more sensitive ctDNA assays, such as incorporation of unique molecular identifiers or other emergent methodologies, it may be possible to assign certain cancer patients to blood-based testing. Tumor analysis would be applied only in cases with lower tumor burden or low ctDNA yields where blood analysis may be unsuccessful, thereby reducing invasive procedures for patients and the associated health care system costs.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0380-z.
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Methods
Ethics approval. This study was undertaken in accordance with the ethical principles originating from the Declaration of Helsinki and in accordance with Good Clinical Practice. The study was approved by the North-West (Preston) National Research Ethics Service in February 2015 (reference 15/NW/0078) and was registered on the NIHR Central Portfolio Management System (reference CPMS ID 39172). All patients were recruited within the ECMT at The Christie NHS Foundation Trust and provided fully informed written consent for provision of tumor and blood samples for genetic analyses. The University of Michigan Flexible Default Model was used for consent 26 that considers cancerrelated genetics from hereditary-related alterations. While the study is focused predominantly on somatic alterations, the default is to inform patients of all genomic alterations, including those that could impact on family or risk of other diseases, unless patients opt out. Specific optional consent was acquired for use of samples for cell culture or animal experiments.
Clinical workflow. TARGET is a two-part study divided into Part A, feasibility of the workflow, ctDNA and tumor sequencing validation, formal reporting and setting up the MTB; and Part B, expansion to match patients to clinical trials and therapies in real time (Fig. 1a) . Here we report results from Part A (N = 100). The study recruited patients referred to the ECMT at The Christie NHS Foundation Trust for consideration of early phase trials. Most patients had exhausted standardof-care treatment options. Patients had to be ECOG PS0-1 and suitable clinical trial candidates; so, no or controlled co-morbidities and acceptable biochemical and hematology parameters in keeping with phase I trial inclusion criteria. The study excluded patients who were declining rapidly, poor performance status or highrisk blood sample donors. Following fully informed written consent, blood and tissue samples were acquired and processed as detailed. Once results were available, data were discussed within a monthly MTB consisting of clinicians, clinical and translational scientists, bioinformaticians, basic scientists and biologists to interpret significance of variants and recommended trials or therapies. Software packages were also used to assist in determination of pathogenicity of variants of unknown significance and a bespoke software package, eTARGET, was developed as a digital solution to integrating clinical and genomic data to facilitate MTB discussion, meeting outcome capture and to serve as a searchable database for data interrogation. The allocation of patients to treatment did not follow a specific algorithm as the process was dynamic and the treatment decision reached by the MTB was on the basis of the specific mutations identified, VAF, associated pathogenicity (on the basis of Qiagen Clinical Interface tiering and evaluation), context in presence of co-mutations, patient treatment history, co-morbidities, fitness and available clinical trial options.
Blood processing and circulating cell-free DNA extraction. Blood was collected in 10 ml BD Vacutainer K2E (EDTA) tubes (Becton Dickinson) and 4 × 10 ml Streck Cell-Free DNA BCT tubes (Streck) during routine phlebotomy. Germline DNA was isolated from EDTA whole blood using the QIAmp Blood Mini Kit (Qiagen) according to manufacturer's instructions, and sheared to 200-300 base pairs (bp) on the Bioruptor Pico (Diagenode). Double-spun plasma was isolated from all Streck ctDNA BCT blood samples within 96 h of blood collection and stored at −80 °C before ctDNA analysis. ctDNA was isolated using the QIAmp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions and/or the QIAsymphony with the Circulating DNA Kit (Qiagen). ctDNA and sheared germline DNA yields were quantified using the TaqMan RNase P Detection Reagents Kit (Life Technologies).
Targeted sequencing of ctDNA and analysis. Sequencing libraries were generated from 0.5 to 25 ng ctDNA, or 25 ng sheared germline DNA in Accel-NGS 2S DNA Library Kits for the Illumina Platform (Swift Biosciences) according to the manufacturer's instructions, with the following modifications. Library amplification and indexing was carried out with KAPA HiFi HotStart PCR Kits (Kapa Biosystems) and NEBNext Index Primers for Illumina (New England Biolabs). For each indexed library, 1 μg were pooled (up to 6 μg) as input for custom capture (641-gene panel) on SureSelectXT Reagent Kits (Agilent) according to the manufacturer's instructions. Captured libraries were amplified using KAPA HiFi HotStart PCR Kits and quantified using the KAPA library quantification qPCR kit (Roche). Libraries were paired-end sequenced on an Illumina NextSeq 500, 2 × 150 bp High Output V2 kit (Illumina).
NGS analysis of ctDNA sequencing data. FASTQ files were generated from the sequencer's output using Illumina bcl2fastq2 software (v.2.17.1.14, Illumina) with the default chastity filter to select sequence reads for subsequent analysis. All sequencing reads were aligned to the human genome reference sequence (GRCh37) using the BWA (v.0.7.12) MEM algorithm. Picard tools (v.2.1.0) were used to mark/remove PCR duplicates and to calculate sequencing metrics. Somatic point mutations were called using both MuTect (v1) and also using the commercial software, Biomedical Genomics Workbench (BGW) v.5.0 (Qiagen) by comparing plasma ctDNA to germline control DNA. Somatic InDels were called using both VarScan and BGW. Mutations called by two independent pipelines (MuTect + BGW or VarScan + BGW) were classed as high confidence and kept. Mutations within the 19-or 24-gene tumor panel were reported as low confidence if only called in a single pipeline. To ensure confidence in reported mutations, a minimum of ten variant reads at the reported loci and a 2.5% VAF threshold were applied to all ctDNA analyses.
Functional annotation of somatic variants was performed using ANNOVAR, the resultant VCF file was analyzed through the Qiagen Clinical Insight for Somatic Cancer platform (Qiagen) and reports were generated for discussion in the TARGET MTB. ' Actionable' was defined as a target of known pathogenic significance for which either a licensed or experimental agent or relevant clinical trial was available at the time of discussion.
CNA analysis of ctDNA. Standard low-pass WGS CNA analysis was performed on eight patient samples as previously described 21 and analyzed using HMM copy. CNA analysis of ctDNA hybridization NGS data was performed using CNVkit software, as previously described 27 , and gene-level amplifications and deletions reported for the 641 cancer-associated genes within the Agilent panel. For comparison with tumor CNA, the gene list was restricted to the 315 genes reported by FoundationOne.
Analysis of tumor DNA. Between one and three 5-µM-thick sections from FFPE tissue specimens were processed to extract genomic DNA using the Roche cobas DNA Sample Preparation Kit. Tumor DNA was analyzed using Sequenome OncoCarta panel v1.0 following the manufacturer's protocol or using the Qiagen Human Clinically Relevant Tumor GeneRead DNAseq Targeted Panel V2, as described. The OncoCarta v1.0 and Qiagen Clinically Relevant Tumor Targeted Panel V2 assays were validated to detect mutations to a VAF of 10% and 4%, respectively. Following PCR-based target enrichment, GeneRead libraries were prepared using Illumina TruSeq PCR Free indexes and reagents. All NGS libraries were paired-end sequenced on an Illumina MiSeq using v2 sequencing chemistry (2 × 150 cycles). Reads were aligned with BWA-MEM (version 0.6.2) hybrid to the human genome build GRCh37 (hg19) followed by local realignment with ABRA (v0.96). Variant calling used a custom bioinformatics analysis pipeline which was validated to detect low-level mosaic calls down to 4% allele fraction, and uses a software consensus between VarScan v2.3.9 and DREEP v0.7. Large indel events were assessed using Pindel (v0.2.4.t).
Variants identified bioinformatically were assessed for trueness and clinical relevance by two independent clinical scientists blinded to each other's interpretation. ACMG/ACGS and AMP guidelines on variant interpretation were followed in the assessment of pathogenicity and clinical relevance of variants.
Statistics and reproducibility. The statistical methods used for each analysis are described within the figure legends and in the Life Science Reporting Summary associated with this letter.
Development of eTARGET.
End-user and data requirements were defined on the basis of the existing TARGET reports, exploration of data sources and interviews with the principal investigator and data controllers. After completion of a successful prototype, a beta version of eTARGET was developed in Microsoft Azure, a secure cloud-computing platform. Components included a storage account for data upload, a database for storing and integrating the data and a web application to view the data. The web application, database and process server are backed up. Network traffic to resources is enforced and controlled by Network Security Group which contains a list of security rules. The data are stored within the European Economic Area and all storage is encrypted.
Access to eTARGET is restricted to members of the MTB who have an account defined in the Azure Active Directory and within the application itself. Access to Azure File Upload Storage is restricted to users with an account in the Azure Active Directory, which has been defined as a contributor to the storage account.
Foundation Medicine FoundationOne testing of tumor. A subset of 51/100 TARGET patients had sufficient biopsy material for FoundationOne testing to be performed on FFPE biopsies of tumor tissue. Of the 51 patients sent for testing 39 were successfully analyzed, with all 39 having at least one variant reported, and 23 having CNA events reported (Supplementary Table 5 ). Theses data were used for comparison of variant and CNA calling from the ctDNA of the corresponding patients. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection ctDNA NGS data was generated on an Illumina NextSeq using v2 sequencing chemistry (2x150cycles) and converted to fastq using Illumina bcl2fastq2 Conversion Software v2.20. All data was aligned using BWA(v 0.7.13) and Qiagen CLC(Version 5.0). For tumour analysis NGS libraries were pair-end sequenced on an Illumina MiSeq using v2 sequencing chemistry (2x150cycles) and all reads aligned using BWA-MEM (version 0.6.2) followed by realignment with ABRA (v0.96)
Data analysis
Data analysis throughout the study was performed using Picard(v 1.96), Bedtools(v 2.20.1), Samtools(0.1.19), GATK(v 3.5), VarScan(v 2.3.9), MuTect(v 1.1.7), Annovar (hg19 reference)(hg19_20170228), Annovar (scripts)(17JUNE2015), COSMIC(v 54_120711), dbSNP(138.b37), QCI(July 2018), eTARGET v1.0, DREEP v0.7, Pindel (v0.2.4.t)
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability All the data generated or analysed during this study are included in this published article or are available from the corresponding author upon reasonable request. Genome data has been deposited at the European Genome-phenome Archive (EGA) which is hosted at the EBI and the CRG, under accession number EGAS00001003407.
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Sample size
The sample size reported in the study is n = 100 patients, which represented the completion of recruitment to Part A of the study. For comparison between ctDNA and tumour results n = 94 as five tumour samples failed analysis and one sample failed ctDNA analysis.
Data exclusions No data is excluded
Replication
Replicate analysis was performed on ctDNA isolation of the first 20 patient samples with 8 ml of plasma from each patient being split into 2 ml aliquots and duplicate isolation performed using manual and QiaSymphony isolation approaches. This data is presented in Extended Data Figure 1 . The majority of the study reports NGS analysis of baseline patient blood samples and did not require replicate analysis.
Randomization No randomization was required as this study was not comparing different treatments
Blinding
No blinding was required for this study as no comparative arms were included
Reporting for specific materials, systems and methods The patient cohort consisted of 38 male and 62 female patients with 22 different tumour types. The median age was 56 years and patients had received a median of two prior lines of therapy.
Recruitment
The study recruited patients referred to the Experimental Cancer Medicine Team at The Christie NHS Foundation Trust for consideration of early phase trials. Most patients had exhausted standard-of-care treatment options. Patients had to be ECOG PS0-1 and suitable clinical trial candidates, thus no or controlled co-morbidities and acceptable biochemical and haematology
